Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10825504 | 1.00 | KDM4E (0.38) | KDM4EALDH1A1APLNRLMNAHTT | |
| SCHEMBL7735453 | 1.00 | KDM4E (0.38) | KDM4EALDH1A1APLNRLMNAHTT | |
| SCHEMBL22007037 | 0.97 | KDM4E (0.34) | KDM4EALDH1A1APLNR | |
| SCHEMBL96365 | 0.97 | KDM4E (0.34) | KDM4EALDH1A1APLNR | |
| SCHEMBL5696574 | 0.95 | KDM4E (0.38) | KDM4EALDH1A1APLNRLMNAHTT | |
| SCHEMBL96617 | 0.92 | KDM4E (0.32) | KDM4EAPLNR | |
| SCHEMBL96759 | 0.90 | APLNR (0.37) | KDM4EALDH1A1APLNR | |
| SCHEMBL14223298 | 0.90 | APLNR (0.37) | APLNR | |
| SCHEMBL25487367 | 0.83 | KDM4E (0.43) | KDM4EALDH1A1APLNRLMNAHTT | |
| SCHEMBL15494142 | 0.83 | KDM4E (0.38) | KDM4EALDH1A1APLNRLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61204178-A | — | — | None | — | — | JP | disclosed |
| US-20120059008-A1 | DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CENERX BIOPHARMA, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| JP-S61204178-A | TRANS-DECALIN DERIVATIVE AND PRODUCTION THEREOF | YAMASA SHOYU CO LTD | 1986-09-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059008-A1 | DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PMP22, CNR2, COQ8A | KDM4E 1168/4885ALDH1A1 2193/4885APLNR 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.